Bibliography

Export 3 results:

Filters: Keyword is Cost-Benefit Analysis [Clear All Filters]

2005

Kamble R, Pant S, Selby GB, Kharfan-Dabaja MA, Sethi S, Kratochvil K, et al. Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts. Transfusion. 2005;45(6):874-8.

2004

Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol. 2004;11(1):26-32.

1996

Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.[Erratum appears in Transfusion 1997 Jan;37(1):109]. Transfusion. 1996;36(7):590-5.